Cita APA

Mateo Valderrama, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., & Jones, R. (2020). Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre, open-label, randomised, phase 2 trial.

Citación estilo Chicago

Mateo Valderrama, Joaquim, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, y Robert Jones. Olaparib in Patients With Metastatic Castration-resistant Prostate Cancer With DNA Repair Gene Aberrations (TOPARP-B): A Multicentre, Open-label, Randomised, Phase 2 Trial. 2020.

Cita MLA

Mateo Valderrama, Joaquim, et al. Olaparib in Patients With Metastatic Castration-resistant Prostate Cancer With DNA Repair Gene Aberrations (TOPARP-B): A Multicentre, Open-label, Randomised, Phase 2 Trial. 2020.